Q3 2024 Evolus Inc Earnings Call Transcript
Key Points
- Evolus Inc (EOLS) achieved a 22% increase in net revenue for the third quarter, reaching $61 million, which is significantly above market growth.
- The company successfully expanded its product portfolio with the approval of Estyme in Europe, positioning itself as one of only five companies globally offering a portfolio of injectable aesthetic products.
- Evolus Inc (EOLS) added over 600 purchasing accounts in the third quarter and maintained a strong reorder rate of over 70%.
- The Evolus Rewards program surpassed 1 million consumers enrolled, demonstrating strong consumer engagement and loyalty.
- The company is on track to launch Evolysse in the U.S. by September 2025, with expectations of further market expansion and operating margin growth.
- Evolus Inc (EOLS) reported a non-GAAP operating loss of $6.7 million in the third quarter, compared to a non-GAAP operating income of $1.1 million in the second quarter.
- The company's cash position decreased from $93.7 million at the end of June 2024 to $85 million at the end of the third quarter.
- There is a noted softness in the filler market, which could impact the launch and performance of Evolysse.
- The company anticipates that profitability may not be sustained every quarter in 2025 due to the launch of Evolysse.
- Evolus Inc (EOLS) narrowed its total net revenue guidance range, indicating potential caution or uncertainty in achieving the upper end of its previous forecast.
Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Third Quarter 2024 Earnings Conference Call. (Operator Instructions) As a reminder, today's conference is being recorded and webcast live. I would now like to turn the conference over to Nareg Sagherian, Vice President and Head of Global Investor Relations and Corporate Communications. Please go ahead.
Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' third quarter 2024 financial results. Our third quarter 2024 press release is now on our website at evolus.com. With me today are David Moatazedi, President and Chief Executive Officer; Rui Avelar, Chief Medical Officer and Head of R&D; and Sandra Beaver, Chief Financial Officer. Today's call will include forward-looking statements. Actual results may differ materially due to the risks and uncertainties outlined in our earnings press release and SEC filings.
These forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
